View in EDS

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.

Saved in:
Bibliographic Details
Title: Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
Authors: Schlaich MP; Dobney Hypertension Centre, Royal Perth Hospital Research Foundation, Medical School, The University of Western Australia, Perth, WA, Australia; Department of Cardiology and Department of Nephrology, Royal Perth Hospital, Perth, WA, Australia. Electronic address: markus.schlaich@uwa.edu.au., Bellet M; Global Clinical Development, Idorsia Pharmaceuticals, Allschwil, Switzerland., Weber MA; Downstate College of Medicine, State University of New York, Brooklyn, NY, USA., Danaietash P; Global Clinical Development, Idorsia Pharmaceuticals, Allschwil, Switzerland., Bakris GL; Department of Medicine, American Heart Association Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL, USA., Flack JM; Division of General Internal Medicine, Hypertension Section, Department of Medicine, Hypertension Section, Southern Illinois University School of Medicine, Springfield, IL, USA., Dreier RF; Global Clinical Development, Idorsia Pharmaceuticals, Allschwil, Switzerland., Sassi-Sayadi M; Department of Biometry, Idorsia Pharmaceuticals, Allschwil, Switzerland., Haskell LP; The Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ, USA., Narkiewicz K; Department of Hypertension and Diabetology, Medical University of Gdańsk, Gdańsk, Poland., Wang JG; Department of Hypertension, The Shanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Corporate Authors: PRECISION investigators
Source: Lancet (London, England) [Lancet] 2022 Dec 03; Vol. 400 (10367), pp. 1927-1937. Date of Electronic Publication: 2022 Nov 07.
Publication Type: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36356632
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Schlaich+MP%22">Schlaich MP</searchLink>; Dobney Hypertension Centre, Royal Perth Hospital Research Foundation, Medical School, The University of Western Australia, Perth, WA, Australia; Department of Cardiology and Department of Nephrology, Royal Perth Hospital, Perth, WA, Australia. Electronic address: markus.schlaich@uwa.edu.au.<br /><searchLink fieldCode="AU" term="%22Bellet+M%22">Bellet M</searchLink>; Global Clinical Development, Idorsia Pharmaceuticals, Allschwil, Switzerland.<br /><searchLink fieldCode="AU" term="%22Weber+MA%22">Weber MA</searchLink>; Downstate College of Medicine, State University of New York, Brooklyn, NY, USA.<br /><searchLink fieldCode="AU" term="%22Danaietash+P%22">Danaietash P</searchLink>; Global Clinical Development, Idorsia Pharmaceuticals, Allschwil, Switzerland.<br /><searchLink fieldCode="AU" term="%22Bakris+GL%22">Bakris GL</searchLink>; Department of Medicine, American Heart Association Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Flack+JM%22">Flack JM</searchLink>; Division of General Internal Medicine, Hypertension Section, Department of Medicine, Hypertension Section, Southern Illinois University School of Medicine, Springfield, IL, USA.<br /><searchLink fieldCode="AU" term="%22Dreier+RF%22">Dreier RF</searchLink>; Global Clinical Development, Idorsia Pharmaceuticals, Allschwil, Switzerland.<br /><searchLink fieldCode="AU" term="%22Sassi-Sayadi+M%22">Sassi-Sayadi M</searchLink>; Department of Biometry, Idorsia Pharmaceuticals, Allschwil, Switzerland.<br /><searchLink fieldCode="AU" term="%22Haskell+LP%22">Haskell LP</searchLink>; The Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Narkiewicz+K%22">Narkiewicz K</searchLink>; Department of Hypertension and Diabetology, Medical University of Gdańsk, Gdańsk, Poland.<br /><searchLink fieldCode="AU" term="%22Wang+JG%22">Wang JG</searchLink>; Department of Hypertension, The Shanghai Institute of Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22PRECISION+investigators%22">PRECISION investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2022 Dec 03; Vol. 400 (10367), pp. 1927-1937. <i>Date of Electronic Publication: </i>2022 Nov 07.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36356632
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(22)02034-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1927
    Titles:
      – TitleFull: Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Schlaich MP
      – PersonEntity:
          Name:
            NameFull: Bellet M
      – PersonEntity:
          Name:
            NameFull: Weber MA
      – PersonEntity:
          Name:
            NameFull: Danaietash P
      – PersonEntity:
          Name:
            NameFull: Bakris GL
      – PersonEntity:
          Name:
            NameFull: Flack JM
      – PersonEntity:
          Name:
            NameFull: Dreier RF
      – PersonEntity:
          Name:
            NameFull: Sassi-Sayadi M
      – PersonEntity:
          Name:
            NameFull: Haskell LP
      – PersonEntity:
          Name:
            NameFull: Narkiewicz K
      – PersonEntity:
          Name:
            NameFull: Wang JG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 03
              M: 12
              Text: 2022 Dec 03
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1474-547X
          Numbering:
            – Type: volume
              Value: 400
            – Type: issue
              Value: 10367
          Titles:
            – TitleFull: Lancet (London, England)
              Type: main
ResultId 1